Technical Analysis for ALNY - Alnylam Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 152.54 -1.20% -1.85
ALNY closed up 1.59 percent on Wednesday, March 27, 2024, on 50 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Up

Date Alert Name Type % Chg
Bollinger Band Squeeze Range Contraction -1.20%
Stochastic Reached Overbought Strength -1.20%
Weak + Overbought Other -1.20%
BB Squeeze + Upper Band Touch Range Contraction -1.20%
Outside Day Range Expansion -1.20%
Above Upper BB Strength -1.20%
Overbought Stochastic Strength -1.20%
Upper Bollinger Band Touch Strength -1.20%
New Uptrend Bullish 0.38%
Bollinger Band Squeeze Range Contraction 0.38%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown 9 minutes ago
Down 1% 40 minutes ago
Fell Below Upper Bollinger Band about 1 hour ago
Up 2% about 22 hours ago
60 Minute Opening Range Breakout about 23 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Alnylam Pharmaceuticals, Inc. Description

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its principal programs under clinical or pre-clinical development include ALN-TTR comprising ALN-TTR02 and ALN-TTRsc for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 for the treatment of hemophilia and rare bleeding disorders; ALN-AS1 for the treatment of acute intermittent porphyria; ALN-PCS for the treatment of hypercholesterolemia; and ALN-TMP for the treatment of hemoglobinopathies, including beta-thalassemia. The company's early stage program comprise ALN-AAT, an RNAi therapeutic targeting the mutant Z-allele in alpha-1-antitrypsin deficiency (AAT deficiency) for the treatment of AAT deficiency-associated liver disease. It also has two partner-based programs in clinical development, including ALN-RSV01 for the treatment of respiratory syncytial virus infection; and ALN-VSP for the treatment of liver cancers, as well as one candidate in pre-clinical development comprising ALN-HTT for the treatment of Huntington's disease. The company has strategic alliances with F. Hoffmann-La Roche Ltd; Arrowhead Research Corporation; Takeda Pharmaceutical Company Limited; Monsanto Company; Isis Pharmaceuticals, Inc.; Novartis Pharma AG; Medtronic, Inc.; Kyowa Hakko Kirin Co., Ltd.; Genzyme Corporation; The Medicines Company; Cubist Pharmaceuticals, Inc; Biogen Idec Inc.; and Ascletis Pharmaceuticals (Hangzhou) Co., Ltd. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Clinical Development Cholesterol Liver Disease Amyloid Amyloidosis Hemoglobin Huntington's Disease Hemophilia Antitrypsin Deficiency Hypercholesterolemia Spinal Muscular Atrophy Genzyme Rna Interference Alnylam Pharmaceuticals Deficiency Hemophilia A Liver Cancer Thalassemia Therapeutic Gene Modulation Transthyretin Treatment Of Hemophilia Hemoglobinopathies Medtronic Acute Intermittent Porphyria Alpha 1 Antitrypsin Deficiency Beta Thalassemia Monsanto

Is ALNY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 218.88
52 Week Low 143.52
Average Volume 929,833
200-Day Moving Average 177.63
50-Day Moving Average 161.83
20-Day Moving Average 149.49
10-Day Moving Average 149.29
Average True Range 4.60
RSI (14) 52.15
ADX 25.73
+DI 23.36
-DI 19.89
Chandelier Exit (Long, 3 ATRs) 147.51
Chandelier Exit (Short, 3 ATRs) 157.46
Upper Bollinger Bands 153.62
Lower Bollinger Band 145.36
Percent B (%b) 1.09
BandWidth 5.53
MACD Line -2.73
MACD Signal Line -4.21
MACD Histogram 1.4882
Fundamentals Value
Market Cap 19.37 Billion
Num Shares 125 Million
EPS -4.11
Price-to-Earnings (P/E) Ratio -37.56
Price-to-Sales 12.38
Price-to-Book 142.92
PEG Ratio -0.49
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 161.71
Resistance 3 (R3) 161.19 158.24 160.49
Resistance 2 (R2) 158.24 156.37 158.50 160.08
Resistance 1 (R1) 156.31 155.22 157.28 156.83 159.68
Pivot Point 153.36 153.36 153.84 153.62 153.36
Support 1 (S1) 151.43 151.49 152.40 151.95 149.10
Support 2 (S2) 148.48 150.34 148.74 148.70
Support 3 (S3) 146.55 148.48 148.29
Support 4 (S4) 147.07